vs

Side-by-side financial comparison of ChargePoint Holdings, Inc. (CHPT) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $105.7M, roughly 2.0× ChargePoint Holdings, Inc.). ChargePoint Holdings, Inc. runs the higher net margin — -49.7% vs -62.0%, a 12.4% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 6.1%). ChargePoint Holdings, Inc. produced more free cash flow last quarter ($-23.6M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -4.5%).

ChargePoint Holdings, Inc. is an American electric vehicle infrastructure company based in Campbell, California. ChargePoint operates the largest online network of independently owned EV charging stations operating in 14 countries and makes some of its technology.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

CHPT vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
2.0× larger
RARE
$207.3M
$105.7M
CHPT
Growing faster (revenue YoY)
RARE
RARE
+19.8% gap
RARE
25.9%
6.1%
CHPT
Higher net margin
CHPT
CHPT
12.4% more per $
CHPT
-49.7%
-62.0%
RARE
More free cash flow
CHPT
CHPT
$77.2M more FCF
CHPT
$-23.6M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-4.5%
CHPT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CHPT
CHPT
RARE
RARE
Revenue
$105.7M
$207.3M
Net Profit
$-52.5M
$-128.6M
Gross Margin
30.7%
Operating Margin
-42.0%
-54.7%
Net Margin
-49.7%
-62.0%
Revenue YoY
6.1%
25.9%
Net Profit YoY
32.4%
3.5%
EPS (diluted)
$-2.23
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHPT
CHPT
RARE
RARE
Q4 25
$105.7M
$207.3M
Q3 25
$98.6M
$159.9M
Q2 25
$97.6M
$166.5M
Q1 25
$101.9M
$139.3M
Q4 24
$99.6M
$164.6M
Q3 24
$108.5M
$139.5M
Q2 24
$107.0M
$147.0M
Q1 24
$115.8M
$108.8M
Net Profit
CHPT
CHPT
RARE
RARE
Q4 25
$-52.5M
$-128.6M
Q3 25
$-66.2M
$-180.4M
Q2 25
$-57.1M
$-115.0M
Q1 25
$-58.8M
$-151.1M
Q4 24
$-77.6M
$-133.2M
Q3 24
$-68.9M
$-133.5M
Q2 24
$-71.8M
$-131.6M
Q1 24
$-94.7M
$-170.7M
Gross Margin
CHPT
CHPT
RARE
RARE
Q4 25
30.7%
Q3 25
31.2%
Q2 25
28.7%
Q1 25
28.2%
Q4 24
22.9%
Q3 24
23.6%
Q2 24
22.1%
Q1 24
19.3%
Operating Margin
CHPT
CHPT
RARE
RARE
Q4 25
-42.0%
-54.7%
Q3 25
-59.8%
-106.9%
Q2 25
-55.1%
-64.8%
Q1 25
-53.9%
-102.6%
Q4 24
-68.4%
-74.3%
Q3 24
-57.8%
-94.6%
Q2 24
-62.7%
-79.1%
Q1 24
-80.2%
-151.9%
Net Margin
CHPT
CHPT
RARE
RARE
Q4 25
-49.7%
-62.0%
Q3 25
-67.1%
-112.8%
Q2 25
-58.5%
-69.0%
Q1 25
-57.7%
-108.5%
Q4 24
-77.9%
-80.9%
Q3 24
-63.5%
-95.7%
Q2 24
-67.1%
-89.5%
Q1 24
-81.8%
-156.8%
EPS (diluted)
CHPT
CHPT
RARE
RARE
Q4 25
$-2.23
$-1.28
Q3 25
$-2.85
$-1.81
Q2 25
$-0.12
$-1.17
Q1 25
$-5.83
$-1.57
Q4 24
$-3.56
$-1.34
Q3 24
$-3.22
$-1.40
Q2 24
$-0.17
$-1.52
Q1 24
$-23.36
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHPT
CHPT
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$180.5M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$38.4M
$-80.0M
Total Assets
$848.0M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHPT
CHPT
RARE
RARE
Q4 25
$180.5M
$421.0M
Q3 25
$194.1M
$202.5M
Q2 25
$195.9M
$176.3M
Q1 25
$224.6M
$127.1M
Q4 24
$219.4M
$174.0M
Q3 24
$243.3M
$150.6M
Q2 24
$261.9M
$480.7M
Q1 24
$327.4M
$112.3M
Stockholders' Equity
CHPT
CHPT
RARE
RARE
Q4 25
$38.4M
$-80.0M
Q3 25
$70.7M
$9.2M
Q2 25
$118.6M
$151.3M
Q1 25
$137.5M
$144.2M
Q4 24
$181.0M
$255.0M
Q3 24
$230.9M
$346.8M
Q2 24
$277.9M
$432.4M
Q1 24
$327.7M
$140.3M
Total Assets
CHPT
CHPT
RARE
RARE
Q4 25
$848.0M
$1.5B
Q3 25
$870.3M
$1.2B
Q2 25
$897.6M
$1.3B
Q1 25
$898.2M
$1.3B
Q4 24
$966.3M
$1.5B
Q3 24
$1.0B
$1.5B
Q2 24
$1.1B
$1.6B
Q1 24
$1.1B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHPT
CHPT
RARE
RARE
Operating Cash FlowLast quarter
$-22.5M
$-99.8M
Free Cash FlowOCF − Capex
$-23.6M
$-100.8M
FCF MarginFCF / Revenue
-22.3%
-48.6%
Capex IntensityCapex / Revenue
1.0%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.6M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHPT
CHPT
RARE
RARE
Q4 25
$-22.5M
$-99.8M
Q3 25
$-6.2M
$-91.4M
Q2 25
$-33.0M
$-108.3M
Q1 25
$-2.7M
$-166.5M
Q4 24
$-30.6M
$-79.3M
Q3 24
$-51.2M
$-67.0M
Q2 24
$-62.5M
$-77.0M
Q1 24
$-41.5M
$-190.7M
Free Cash Flow
CHPT
CHPT
RARE
RARE
Q4 25
$-23.6M
$-100.8M
Q3 25
$-7.5M
$-92.7M
Q2 25
$-34.0M
$-110.7M
Q1 25
$-4.6M
$-167.8M
Q4 24
$-33.4M
$-79.5M
Q3 24
$-55.0M
$-68.6M
Q2 24
$-66.0M
$-79.0M
Q1 24
$-46.2M
$-193.9M
FCF Margin
CHPT
CHPT
RARE
RARE
Q4 25
-22.3%
-48.6%
Q3 25
-7.6%
-58.0%
Q2 25
-34.9%
-66.5%
Q1 25
-4.5%
-120.5%
Q4 24
-33.5%
-48.3%
Q3 24
-50.7%
-49.2%
Q2 24
-61.7%
-53.7%
Q1 24
-39.9%
-178.2%
Capex Intensity
CHPT
CHPT
RARE
RARE
Q4 25
1.0%
0.5%
Q3 25
1.3%
0.8%
Q2 25
1.1%
1.5%
Q1 25
1.9%
1.0%
Q4 24
2.8%
0.1%
Q3 24
3.5%
1.2%
Q2 24
3.2%
1.4%
Q1 24
4.1%
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHPT
CHPT

Products$56.4M53%
License And Service$42.0M40%
Other$7.3M7%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons